Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1b Multicenter Study of IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Next Previous
Trial Profile

An Open-label, Phase 1b Multicenter Study of IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Sintilimab (Primary)
  • Indications Endometrial cancer; Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 27 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 02 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top